Abstract
Radiation-induced sarcoma (RIS) is among the neoplasms potentially caused by radiation therapy (RT) for brain tumors. However, the clinical characteristics of and ideal treatment for RIS are unclear. We analysed our case experience and conducted a comprehensive literature review to reveal the characteristics of brain and cranial RIS. We analysed 165 cases of RIS from the literature together with the RIS case treated at our institution. In each case, the latency period from irradiation to the development of each RIS and the median overall survival (OS) of the patients was analysed by Kaplan-Meier analysis. Spearman's correlation test was used to determine the relationship between the latency period and radiation dose or age at irradiation. The mean age at the development of RIS was 39.63±17.84years. The mean latency period was 11.79±8.09years. No factors associated with early development of RIS were detected. The median OS was 11months, with fibrosarcoma showing significantly shorter OS compared with osteosarcoma and other sarcomas (p=0.0021), and intracranial RIS showing a worse prognosis than extracranial RIS (p<0.0001). Patients treated with surgery (p<0.0001) and postoperative chemotherapy (p=0.0157) for RIS presented significantly longer OS, whereas RT for RIS was not associated with a survival benefit. Although prognosis for RIS is universally poor, pathological characteristics and locations are associated with worse prognosis. Surgery and chemotherapy may be the ideal treatment strategies for RIS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.